Artificial intelligence (AI)-designed antibodies represent a transformative approach to antibody discovery and engineering, leveraging machine learning, structural modeling, and generative AI algorithms to accelerate the identification and optimization of therapeutic candidates.
- By analyzing large datasets of antibody sequences, structures, and antigen interactions, AI can predict antigen-binding regions, improve affinity and specificity, reduce immunogenicity, and optimize developability properties such as stability and manufacturability.
- Compared with traditional antibody discovery methods, AI-driven platforms can significantly shorten development timelines, reduce experimental costs, and enable the design of novel antibodies against challenging targets.
- AI-designed antibodies are a powerful tool for next-generation therapeutics, diagnostics, and precision medicine, validated in our advanced laboratory.
Programs at IMGENEX INDIA
Several antibodies against inflammatory cytokines and for use in CAR-T therapies are under development using AI at IMGENEX INDIA. View our pipeline.